Filings signal: Despite Covid losses, pharma earnings are promising
Each week, Pharmaceutical Technology’s journalists pick out insights from company filings that highlight sentiments in our sector. These filings signals…
Roche
-
-
EC approves Roche’s Evrysdi as first at-home treatment for spinal muscular atrophy
The European Commission has granted marketing authorisation to PTC Therapeutics’ Evrysdi (risdiplam) for the at-home treatment of spinal muscular atrophy…
-
Find out about the foundation for the first drugs using microbiome bacteria in the latest issue of Pharma Technology Focus
Pharma Technology Focus is now available on all devices. Read it for free here. In this issue we find out…
-
China approves Roche’s lung cancer drug Alecensa
Roche’s Alecensa (alectinib) drug has secured marketing authorisation from the China National Drug Administration (CNDA) to treat advanced non-small cell…
-
Roche and PureTech to develop oral antisense oligonucleotides
Roche has signed a multi-year partnership with US-based biopharmaceutical company PureTech Health for the development of its oral antisense oligonucleotide…
-
Roche gains FDA breakthrough status for Tecentriq combination
Roche has obtained breakthrough therapy designation from the US Food and Drug Administration (FDA) for the combination of Tecentriq (atezolizumab)…